LungLife AI, INC Result of AGM

RNS Number : 2975R

LungLife AI, INC

05 June 2024

 

LungLife AI, Inc.

("LungLife" or the "Company")

 

Result of Annual General Meeting

 

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that at its Annual General Meeting, held at earlier today, all 10 resolutions put to members were passed on a poll.

 

Full details of the voting will be available shortly on the Company website here: https://lunglifeai.com/investors/financial-information-documents-presentations/

 

For further information please contact:

 

LungLife AI, Inc.	www.lunglifeai.com
Paul Pagano, CEO	Via Walbrook PR
David Anderson, CFO
Investec Bank plc (Nominated Adviser & Broker)	Tel: [phone]
Virginia Bull / Cameron MacRitchie / Lydia Zychowska
Goodbody (Joint Broker)	Tel: [phone]
Tom Nicholson / Cameron Duncan
Walbrook PR Limited	Tel: [phone] or [e-mail]
Alice Woodings / Phillip Marriage	Mob: [phone]

 

 

About LungLife

LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com

 

Our Purpose is to be a driving force in the early detection to lung cancer.  Our Vision is to invert the 20:80 ratio such that in years to come at least 80% of lung cancer is detected early.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

RAGEAKKSEFLLEFA